Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event

AmericanPharmaceuticalReviewNovember 12, 2021

Tag: Merck , vericiguat , Verquvo

PharmaSources Customer Service